Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

Mahrukh M. Syeda, David Polsky, James H. Garrett et al.|The Lancet Oncology|2025

Cited by 28